Dergiler / Medicine Science / 2016 / Cilt: 5 - Sayı: 1

Danazol one Month Treatment of Thrombocytopenia in Chronic Hepatitis C

Sayfa
209–221
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Danazol one month treatment is effective for increasing and maintaining platelet levels and can be considered a treatment option for thrombocytopenia in chronic hepatitis C virus

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Thrombocytopenia is frequently observed in patients with chronic hepatitis C virus.
📊
Temel Bulgular & Veri:Moderate and severe thrombocytopenia (<75,000/mm³) may interfere with diagnostic or therapeutic elective procedures and can be a limiting factor when considering these interventions.
💡
Sonuç & Katkı:Danazol one month treatment is effective for increasing and maintaining platelet levels and can be considered a treatment option for thrombocytopenia in chronic hepatitis C virus
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Thrombocytopenia is frequently observed in patients with chronic hepatitis C virus. Moderate and severe thrombocytopenia (<75,000/mm³) may interfere with diagnostic or therapeutic elective procedures and can be a limiting factor when considering these interventions. The aim of this study was to evaluate the efficacy of one month Danazol treatment for increasing and maintaining platelet levels in chronic hepatitis C virus patients associated with thrombocytopenia. 48 patients with chronic hepatitis C virus and platelet levels less than 75000/mm³ were included. Danazol was given in conventional dose 400 mg (200 mg bid) per oral after meal for one month, the monitoring of platelet levels was performed during treatment, at the end of treatment and at three months after the end of treatment. After one month with Danazol treatment the mean platelet levels increased significantly from 60400 + 11100/mm³ to a level of 90700 + 31400/mm³. Danazol increased the platelet levels of 33 (68.8%) patients more than 75000/mm³ and 5 (10.4%) patients had an increase in platelet levels but did not exceed 75,000/mm³, while in 10 (20.8%) patients platelet levels declined and considered unresponsive to Danazol. The percentage of patients with moderate thrombocytopenia (50000 to 75000/mm³) decreased significantly from 83.3% to 20.8% after Danazol treatment. Danazol one month treatment is effective for increasing and maintaining platelet levels and can be considered a treatment option for thrombocytopenia in chronic hepatitis C virus

🔖

Bu Makaleye Atıf Yap

DAWOD, H. M., MONEM, S. M. A. (2016). Danazol one Month Treatment of Thrombocytopenia in Chronic Hepatitis C. Medicine Science, Cilt: 5 - Sayı: 1, 209–221. https://ajindex.com/articles/277525

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Lavie KS, MiCallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocytopenia among patients with chronic hepatitis C: Asystematic review. J Viral Hepat. 2011;18(1):1-7
  2. Giannini EG, Afdhal NH, Sigal SH, Muir AJ, Reddy KR, Vijayaraghavan S, Elkashab M, Romero-Gómez M, Dusheiko GM, Iyengar M, Vasey SY, Campbell FM, Theodore D. Non cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.J Gastroenterol Hepatol. 2015;30(8):1301-8
  3. Fouad YM1.Chronic hepatitis C-associated thrombocytopenia: aetiology and management. Trop Gastroenterol. 2013;34(2):58-67
  4. Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol. 2001;68(3):202-9
  5. Giannini E, Borro P, Botta F, Fumagalli A, Malfatti F, Podesta E, Romagnoli P, Testa E. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol. 2002;37(5):572-7
  6. Alvarez GC, Gomez-Galicia D Rodrigu-Fragos, Marina VM, Dorantes LC, SanchezAleman M., Mendez- Sanchez N, Esparza JR. Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin. Ann of Hepatol. 2011;10(4):458-68
  7. Schreiber AD, Chien P, Tomaski A, Cines DB. Effect of danazol in immune thrombocytopenic purpura. N Engl J Med. 1987;316(9):503-8
  8. Mylvaganam R, Ahn YS, Harrington WJ, Kim CI. Immune modulation by danazol in autoimmune thrombocytopenia. Clin Immunol Immunopathol. 1987;42(3):281-7
  9. West SG, Johnson SC. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med. 1988;108(5):703-6
  10. Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med. 1983;308(23):1396- 9
  11. Ahn YS, Horstman LL. Idiopathic thrombocytopenic purpura: Pathology and management. Int J Hematol. 2002;76(Suppl 2):123-31
  12. Maloisel F, Andres E, Zimmer J, Noel E, Zamfir A, Koumarianou A, Dufour P. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: Long term results. Am J Med. 2004;116(9):590-4
  13. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH; TPL102357 Study Group. Eltrombopage for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):222